Patents by Inventor Richard T. Coughlin
Richard T. Coughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210263047Abstract: The levels of prouroguanylin (proUGN), or fragments thereof, present in blood are normally low in humans and are proposed to be involved in the physiologic regulation of oral and vascular salt levels in the body. When certain kidney related diseases or kidney dysfunctions occur, the level of proUGN or fragments thereof can rise dramatically and significantly. This rise of proUGN in the serum can be used as a marker to diagnose and, in turn, treat kidney disease, or monitor disease progression of kidney dysfunction, or can be used to predict the outcome of a treatment program for kidney disease and/or dysfunction. The level of proUGN or fragments thereof can be measured by a novel immunological assay, and a positive result above a cut-off value is diagnostic for chronic kidney disease (CKD). The calibration of that immunological assay can be done best by using a full-length appropriately folded and secreted recombinant human protein without any N?- or C?-terminal tags made in a human kidney cell line.Type: ApplicationFiled: January 28, 2021Publication date: August 26, 2021Inventors: Richard T. COUGHLIN, Stephen L. CARRITHERS, Aaron L. CARRITHERS, Brennan M. CARRITHERS
-
Patent number: 8461323Abstract: The present invention relates, in general, to polypeptides having antigenic epitopes from granulocytic ehrlichia (GE) proteins and methods of use thereof.Type: GrantFiled: January 9, 2012Date of Patent: June 11, 2013Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 8435495Abstract: The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.Type: GrantFiled: June 25, 2012Date of Patent: May 7, 2013Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20120270232Abstract: The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.Type: ApplicationFiled: June 25, 2012Publication date: October 25, 2012Applicant: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20120178102Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: January 9, 2012Publication date: July 12, 2012Applicant: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 8093008Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: August 18, 2010Date of Patent: January 10, 2012Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20110045605Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: August 18, 2010Publication date: February 24, 2011Inventors: Cheryl Murphy, James Storey, Geraid A. Beltz, Richard T. Coughlin
-
Patent number: 7863434Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: February 26, 2001Date of Patent: January 4, 2011Assignee: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20100088774Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: February 26, 2001Publication date: April 8, 2010Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 6794181Abstract: Disclosed is a method for purifying a antibiotic from a crude or partially purified solution containing the lantibiotic. In preferred embodiments, the lantibiotic is nisin, although the common structural features of lantibiotics dictate the effectiveness of the disclosed purification methods for other members of the lantibiotic genus. The method includes the step of forming an incubation mixture comprising the solution containing the lantibiotic and a proteolytic enzyme, and incubating the mixture under conditions optimized for selective proteolytic activity.Type: GrantFiled: October 9, 2002Date of Patent: September 21, 2004Assignee: ImmuCell CorporationInventors: Richard T. Coughlin, Joseph H. Crabb
-
Publication number: 20040072333Abstract: Disclosed is a method for purifying a lantibiotic from a crude or partially purified solution containing the lantibiotic. In preferred embodiments, the lantibiotic is nisin, although the common structural features of lantibiotics dictate the effectiveness of the disclosed purification methods for other members of the lantibiotic genus. The method includes the step of forming an incubation mixture comprising the solution containing the lantibiotic and a proteolytic enzyme, and incubating the mixture under conditions optimized for selective proteolytic activity.Type: ApplicationFiled: October 9, 2002Publication date: April 15, 2004Applicant: ImmuCell CorporationInventors: Richard T. Coughlin, Joseph H. Crabb
-
Patent number: 6306394Abstract: Nucleic acids encoding eleven different proteins of granulocytic erhlichia (GE), a tick-borne intracellular bacteria, have been isolated and sequenced completely. These DNAs were isolated as immunoreactive clones from a Lambda Zap II genomic library of GE DNA purified from infected HL60 cells. Three of the clones, E8, E80, and E46, contain open reading frames for four highly homologous proteins which appear to be part of a multigene family resembling the MSP-2 gene family of Anaplasma marginale. One clone, B3, contained a gene encoding the heat shock 70 protein. The other clones (W20, E74, and E82) contain open reading frames for proteins which have some homology to other bacterial proteins present in the nucleotide and protein databases. These and other GE antigens identified by immunoscreening of the genomic library are potentially useful as diagnostic reagents and vaccine candidates for GE.Type: GrantFiled: April 24, 1998Date of Patent: October 23, 2001Assignee: Aquila Biopharmaceuticals Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 6284238Abstract: The present invention relates, in general, to granulocytic Ehrlichia. In particular, the present invention relates to a human promyelocytic leukemia cell line infected with granulocytic Ehrlichia, a method of continually growing granulocytic Ehrlichia, vaccines comprising granulocytic Ehrlichia or granulocytic Ehrlichia antigens, methods of preventing ehrlichiosis in an animal, antibodies to granulocytic Ehrlichia, and methods for identifying granulocytic Ehrlichia in an animal.Type: GrantFiled: June 6, 1995Date of Patent: September 4, 2001Assignee: Aquila Biopharmaceuticals, Inc.Inventors: Richard T. Coughlin, Cindy Gingrich-Baker
-
Patent number: 6204252Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: April 24, 1998Date of Patent: March 20, 2001Assignee: Aquila Biopharmaceuticals, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 5976860Abstract: The present invention relates, in general, to granulocytic Ehrlichia. In particular, the present invention relates to a cell line selected from the group consisting of a promyelocytic leukemia cell line, an acute myelogenous leukemia cell line, a histiocytic lymphoma cell line, a monocyte macrophage-like cell line, an acute monocytic leukemia cell line, and an embryonic lung cell line wherein the cell line is infected with granulocytic Ehrlichia, a method of continually growing granulocytic Ehrlichia, vaccines comprising granulocytic Ehrlichia or granulocytic Ehrlichia antigens, methods of preventing ehrlichiosis in an animal, antibodies to granulocytic Ehrlichia, and methods for identifying granulocytic Ehrlichia in an animal.Type: GrantFiled: March 11, 1996Date of Patent: November 2, 1999Assignee: Aquila Biopharmaceuticals, Inc.Inventors: Richard T. Coughlin, Cindy Gingrich-Baker
-
Patent number: 5473784Abstract: A body board is provided having upper and lower plastic components defining an outer plastic shell having a hollow interior. The underside of the plastic shell defines a pair of runners which serve to space handholds disposed about the periphery of the body board from the ground on which the body board rests. A fiberglass reinforcement structure having upper and lower sheets is disposed within the hollow interior. The fiberglass sheets are bent or curved across the width of the body board to provide increased structural support for resistance to deflection or sagging of the body board when supporting a patient. The thickness of the upper and lower plastic shell components and the thickness of the upper and lower sheets of the fiberglass reinforcement structure are substantially uniform over a central x-ray region. Also, none of the upper and lower plastic shell components or the upper and lower fiberglass sheets extend vertically over any portion thereof disposed within the central x-ray region.Type: GrantFiled: July 19, 1994Date of Patent: December 12, 1995Assignee: Arizona E.M.S. Products, Inc.Inventors: Drue C. Nixon, Daniel B. Soulvie, Richard T. Coughlin
-
Patent number: 5231003Abstract: Monoclonal antibodies specific for Toxin B of Clostridium difficile are provided. Further, methods for making and using the antibodies are given, particularly the use of the antibodies for the detection of C. difficile.Type: GrantFiled: May 11, 1990Date of Patent: July 27, 1993Assignee: Cambridge Bioscience CorporationInventors: Richard T. Coughlin, Dante J. Marciani